BOSTON--(BUSINESS WIRE)--ZappRx, a digital health company that reduces the administrative burden associated with prescribing specialty medications, is exhibiting at the annual PHA International Conference this weekend from June 29 – July 1, in Orlando, FL. The company will be showcasing its revolutionary technology that digitizes and automates the inefficient specialty prescribing and prior authorization process. Members of the ZappRx team will also be on site to provide attendees with updates on recent, notable customer partnerships and company growth.
The first half of 2018 was one of significant growth for the company. According to ZappRx CEO and founder, Zoë Barry, “As we scale ZappRx, our customers and their patients continue to serve as the primary motivation behind our product innovation and corporate growth. It’s imperative for our team to not only strengthen our core product for existing customers but also to identify solutions that will address the future needs of prospective customers. With deep market penetration in pulmonology, the PHA conference is an ideal venue for us to update the industry on what we’ve been up to and where the company is heading.”
The company has also made a number of announcements in recent months regarding strategic partnerships and certifications, further highlighting their momentum across stakeholders in the specialty pharmaceutical space, including:
- Integration with FDB MedsSTracker® eRx further accelerates the delivery of specialty drugs to patients and reduces burden for physicians.
- Extended partnership with PARx Solutions supports ZappRx’s expansion into additional, new disease areas, outside of pulmonology.
- ZappRx also received the HITRUST CSF® Certification, which verifies the company is appropriately managing privacy and risk, and has met the key regulations and industry-defined requirements.
To meet customer demand, ZappRx has expanded internally as well, doubling its sales and customer service teams, expanding the product team, and moving into a new, larger headquarters in the center of Boston.
“Working at ZappRx, it’s evident the entire team is passionate about the solutions we are developing for patients in need of specialty medications and the clinicians who care for them,” said Leslie Hoyt, chief growth officer, ZappRx. “Our continuous growth is undoubtedly a result of the smart, diverse and talented team Zoë has built, and the innovation they bring to a space in such desperate need of change. We’re looking forward to showcasing everything that ZappRx has achieved at PHA International and hearing real-time feedback to better improve our solutions in the months and years ahead.”
If you’re attending PHA International, please be sure to visit ZappRx at booth #507. To learn more about ZappRx and its revolutionary application for specialty prescribing and prior authorization, please visit them at www.zapprx.com.
ZappRx streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for specialty prescribing — including pharmacy information, payer/prior authorization requirements, and relevant clinical history. ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for faxes and phone calls. The platform is currently live in three disease areas, including Pulmonary Arterial Hypertension (PAH), Idiopathic Pulmonary Fibrosis (IPF), and Cystic Fibrosis, with plans to expand to support prescribing for other areas, including gastroenterology, rheumatology, neurology, and oncology conditions.